Torsten Hinz
YOU?
Author Swipe
View article: Management of moderate to severe psoriasis with brodalumab—Real‐world evidence from the <scp>LIBERO</scp> study
Management of moderate to severe psoriasis with brodalumab—Real‐world evidence from the <span>LIBERO</span> study Open
Background Brodalumab, a fully human monoclonal immunoglobulin IgG2 antibody that binds the human interleukin 17 receptor subunit A, is available for the treatment of moderate‐to‐severe plaque psoriasis in Europe since September 2017, but …
View article: Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study <scp>TILOT</scp>
Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study <span>TILOT</span> Open
Background Plaque psoriasis is a chronic inflammatory disorder affecting the skin and impacting quality of life. Tildrakizumab (TIL) is an IL‐23 inhibitor licensed for moderate‐to‐severe plaque psoriasis. Regulatory approval of medicinal p…